Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05709301 | Not yet recruiting | Parkinson Disease

Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease
Sponsor:

Foundation Research Institute of the Hospital de la Santa Creu i Sant Pau

Brief Summary:

Phase II, multi-centric, randomized, double-blinded, placebo-controlled, parallel design clinical trial to evaluate the safety, tolerability and efficacy of Donepezil in patients with Mild Cognitive Impairment in Parkinson's Disease (PD-MCI). A total of 120 patients with PD-MCI will be randomized to 12 months of oral Donepezil 10mg or matching placebo (1:1). Primary and co-primary efficacy endpoints are cognitive and functional cognitive scales: PD-CRS and PD-CFRS. Secondary efficacy endpoints include: cognitive tests evaluating attention, executive functions, language, memory and visuospatial domain; mood, anxiety, and apathy scales; questionnaires to evaluate quality of life; and subjective impression scales. Serum Neurofilament light chain, genetic screening of GBA, ApoE and MAPT, and Magnetic Resonance Imaging will be performed in a subset of these patients. The study will be conducted in 20 different centers around Spain. The Movement Disorders Unit of the Neurology Department at Sant Pau Hospital (Barcelona, Spain) will be the coordinating center.

Condition or disease

Parkinson Disease

Mild Cognitive Impairment

Intervention/treatment

Donepezil Hydrochloride

Placebo

Phase

Phase 2

Study Type : Interventional
Estimated Enrollment : 120 participants
Masking : Quadruple
Primary Purpose : Treatment
Official Title : Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease
Actual Study Start Date : October 1, 2023
Estimated Primary Completion Date : November 1, 2025
Estimated Study Completion Date : November 1, 2025
Arm Intervention/treatment

Experimental: Donepezil

Drug: Donepezil Hydrochloride

Placebo Comparator: Placebo

Drug: Placebo
Ages Eligible for Study: 50 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • Age 50-80
  • PD diagnosis according to MDS criteria
  • Hoehn and Yahr stage I-III
  • Persistent subjective cognitive complaints for at least 6 months
  • MDS PD-MCI Level I and Level II criteria
  • Persistent PD-MCI for at least 3 months
  • Stable dopaminergic treatment for at least 1 month
Exclusion Criteria
  • PD dementia criteria
  • Severe motor complications
  • DBS or any brain condition that may be contributing to cognitive impairment
  • Active psychosis, major hallucinations, HADS ≥11, active impulse control disorder, or other active severe behavioral disorders.
  • Treatment under anticholinergics, cholinergic enhancers, or neuroleptics.
  • History of symptomatic arterial hypotension.
  • Hypersensitivity or intolerance to donepezil or any of the excipients
  • Pregnancy
  • Unstable medical or surgical condition
  • Any other significant observation that, in the investigator's opinion, would contraindicate participation in the study.
Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Location Details

Please Choose a site

Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations